Gu Yiqun, Liang Xiaowei, Wu Weixiong, Liu Minli, Song Shuxiu, Cheng Lifa, Bo Liwei, Xiong Chengliang, Wang Xinghai, Liu Xiaozhang, Peng Lin, Yao Kangshou
Department of Male Clinic Research, National Research Institute for Family Planning, 12 Da Hui Si Road, Haidian District, Beijing 100081, China.
J Clin Endocrinol Metab. 2009 Jun;94(6):1910-5. doi: 10.1210/jc.2008-1846. Epub 2009 Mar 17.
Hormonal male contraceptive regimens effectively and reversibly suppress sperm production, but there are few large-scale efficacy studies.
The safety, contraceptive efficacy, reversibility, and feasibility of injectable testosterone undecanoate (TU) in tea seed oil as a hormonal male contraceptive was assessed.
This was a multicenter, phase III, contraceptive efficacy clinical trial.
A total of 1045 healthy fertile Chinese men were recruited throughout China into the study.
INTERVENTION(S): Injections of 500 mg TU were administered monthly for 30 months. A definition of severe oligozoospermia (< or =1 x 10(6)/ml) was used as a criterion of spermatogenic suppression and as the threshold for entering the contraceptive efficacy phase.
MAIN OUTCOME MEASURE(S): The primary outcome was pregnancy rate in the partner. Other outcomes include: semen parameters, testis volumes, reproductive hormone levels, and safety laboratory tests.
Forty-three participants (4.8%) did not achieve azoospermia or severe oligozoospermia within the 6-month suppression phase. A total of 855 participants entered into the efficacy phase, and 733 participants completed monthly TU treatment and follow-up. There were nine pregnancies in 1554.1 person-years of exposure in the 24-month efficacy phase for a cumulative contraceptive failure rate of 1.1 per 100 men. The combined method failure rate was 6.1%, comprising 4.8% with inadequate suppression and 1.3% with postsuppression sperm rebound. No serious adverse events were reported. Spermatogenesis returned to the normal fertile reference range in all but two participants.
Monthly injection of 500 mg TU provides safe, effective, reversible, and reliable contraception in a high proportion of healthy fertile Chinese men.
激素男性避孕方案能有效且可逆地抑制精子生成,但大规模疗效研究较少。
评估注射用十一酸睾酮(TU)溶于茶籽油中作为激素男性避孕药的安全性、避孕效果、可逆性和可行性。
这是一项多中心、III期避孕效果临床试验。
在中国各地共招募了1045名健康可育的中国男性参与研究。
每月注射500毫克TU,持续30个月。将严重少精子症(<或=1×10⁶/毫升)的定义用作生精抑制的标准以及进入避孕效果阶段的阈值。
主要结局是伴侣的妊娠率。其他结局包括:精液参数、睾丸体积、生殖激素水平和安全性实验室检查。
43名参与者(4.8%)在6个月的抑制期内未达到无精子症或严重少精子症。共有855名参与者进入疗效阶段,733名参与者完成了每月的TU治疗和随访。在24个月的疗效阶段,1554.1人年的暴露中有9例妊娠,累积避孕失败率为每100名男性1.1例。联合方法失败率为6.1%,其中抑制不足占4.8%,抑制后精子反弹占1.3%。未报告严重不良事件。除两名参与者外,所有参与者的精子发生均恢复到正常生育参考范围。
每月注射500毫克TU可为高比例的健康可育中国男性提供安全、有效、可逆且可靠的避孕方法。